Learn how to save buying Copegus medication online - Find best Copegus drugstores on line - We only recommend trusted websites - Hassle free ordering - Fast cheap delivery and more...
Copegus Medication Information
Copegus is an anti-viral drug, which when metabolised resembles purine RNA nucleotides. In this form it interferes with RNA metabolism required for viral replication. Copegus prescription generic name is Ribavirin. Doctors may prescribe Copegus for the treatment of Chronic Hepatitis C, Influenza, Flaviviruses, Viral Hemorrhagic Fever and DNA and RNA Viruses. Copegus has been used (in combination with ketamine, midazolam, and amantadine) in treatment of rabies. Copegus medicine is available in 100mg Tablets and 200mg Tablets. Other prescription names for medications containing Ribavirin (Copegus main ingridient) are Biopolymers, Rebetol, Rebetron, Ribamidil, Ribasphere, Ribavin, Tribavirin, Varazid, Vilona and Virazole.
FluMist® Begins Shipping for 2010-2011 Influenza Season
GAITHERSBURG, Md., July 23 /PRNewswire/ -- MedImmune announced today that it has begun shipping FluMist® (Influenza Vaccine Live, Intranasal) to influenza vaccine distributors who service health care providers throughout the United States.
(Photo; http://photos.prnewswire.com/prnh/20070516/NEW026 )
(Photo: http://www.newscom.com/cgi-bin/prnh/20070516/NEW026 )
MedImmune expects to provide approximately 15 million doses of its trivalent (three-strain) nasal spray flu vaccine for the 2010-2011 influenza season through a variety of private health care practices, public health departments, school-located vaccination programs, military bases, and other venues.
FDA Clears First 2009 H1N1 Influenza Virus Test Previously Available Under Emergency Use Authorization
Clearance will allow continued use of Simplexa Influenza A H1N1 (2009) test
SILVER SPRING, Md., May 24 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced it has cleared the Simplexa Influenza A H1N1 (2009), a test for the 2009 H1N1 Influenza Virus in patients with signs and symptoms of respiratory infection.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)
Until this clearance, tests for 2009 H1N1 Influenza were only available through an Emergency Use Authorization (EUA), which allows the FDA, based on the evaluation of available data, to authorize the use of unapproved or uncleared medical products or unapproved or uncleared uses of approved or cleared medical products, during the time a declara...
New Prime Therapeutics Study Finds Antiviral Medications Were Not Hoarded During H1N1 Flu Season
ST. PAUL, Minn., May 20 /PRNewswire/ -- Despite concerns from public health officials, influenza antiviral drugs were not hoarded during the recent H1N1 flu season, according to a new analysis presented recently at the Academy of Managed Care Pharmacy's 22nd Annual Meeting in San Diego by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management.
Chimerix Initiates Phase 1 Study of CMX157
RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV).
Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Offic
RESEARCH TRIANGLE PARK, N.C., May 4 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch has been appointed President and Chief Executive Officer.
